February 1999 Established D.Western Therapeutics Institute, Inc. in Nagoya, Aichi Prefecture for the purpose of conducting pharmaceutical research and development (five million yen capitalization)
September 2002 Signed a development and implementation agreement with Kowa Co., Ltd. for K-115, a drug for treating glaucoma
November 2004 Changed from a limited company to a joint-stock corporation (10 million yen capitalization)
December 2006 Entered into an industry-academia-government collaboration agreement with Mie University Faculty of Medicine for joint research, and jointly established Institute of Human Research Promotion and Drug Development at the University
October 2009 Listed on JASDAQ Securities Exchange NEO Market (now Tokyo Stock Exchange Growth market)
December 2014 GLANATEC® ophthalmic solution 0.4% (generic name: Ripasudil hydrochloride hydrate, K-115) for glaucoma launched in Japan
June 2015 Signed an in-licensing agreement to acquire exclusive Japan license for an ophthalmic drug (DW-1001)
November 2015 Made Japan Innovative Therapeutics Inc. a consolidated subsidiary
April 2017 Received transfer of business related to an ophthalmic surgical adjuvant (DW-1002)
March 2018 Initiatied Phase I/IIa clinical trials of glaucoma treatment (H-1337), DWTI’s first in-house developed product, in the U.S.
August 2018 Signed a joint research and licensing agreement with U.S.-based Glaukos Corporation for glaucoma drugs
September 2018 Phase I/IIa clinical trials of H-1337 glaucoma treatment completed in the U.S.
August 2019 Submitted an Investigational New Drug (IND) application for Phase II clinical trials in the U.S. of Ripasudil hydrochloride hydrate as treatment for Fuchs endothelial corneal dystrophy (K-321)
December 2019 Signed an agreement with Rohto Pharmaceutical Co., Ltd., granting exclusive Japan license for ophthalmic drug DW-1001
February 2020 Phase III clinical trials began in Japan for a fixed combination drug for treating glaucoma (Ripasudil hydrochloride hydrate and Brimonidine tartrate [K-232])
April 2020 Ophthalmic surgical adjuvant DW-1002 (TissueBlue™) launched in the U.S.
August 2020 Signed a joint development agreement with MEDRx Co., Ltd. for DW-5LBT neuropathic pain treatment
August 2020 Applied for approval of DW-5LBT neuropathic pain treatment in the U.S.
September 2020 Added new disease types (corneal and retinal disorders) for joint research with U.S.-based Glaukos, and signed a new licensing agreement
October 2021 Ophthalmic surgical adjuvant DW-1002 (TissueBlue™) launched in Canada
November 2021 Applied for approval of K-232 glaucoma and ocular hypertension in Japan
March 2022 Phase I clinical trials of DW-1001 began in Japan
June 2022 Signed a joint development agreement with ActualEyes Inc. for DWR-2206 regenerative cell therapy for bullous keratopathy
August 2022 Phase III clinical trials of K-321 for Fuchs endothelial corneal dystrophy began in U.S.
December 2022 GLA-ALPHA® combination ophthalmic solution (generic name: Ripasudil hydrochloride hydrate, brimonidine tartrate, K-232) for glaucoma and ocular hypertension launched in Japan
Initiatied Phase IIb clinical trials of glaucoma treatment (H-1337)
March 2024 Phase II clinical trials of DWR-2206 for bullous keratopathy began in Japan